Altimmune: Pay

Altimmune paid its 4 named executives $15.2M in total in FY2025 (Dec). CEO Vipin K. Garg, Ph.D. was paid $8.0M of that.

Pay$100 in the stock at the end of FY21 → $39
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Vipin K. Garg, Ph.D.Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
M. Scott Harris, M.D.former Chief Medical Officer
FY2025 (Dec)
FY2022 (Dec)
2 years
Christophe Arbet-Engels, M.D., Ph.D.Chief Medical Officer
FY2025 (Dec)
1 year
M. Scot Roberts, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $4.2M. The CEO of Altimmune was paid $8.0M, 93% above the median.

  1. 1Altimmune
  2. 2Solid Biosciences
  3. 3Savara
  4. 4aTYR Pharma
  5. 5Arbutus Biopharma
  6. 689bio, Inc.Not disclosed
  7. 7Akero Therapeutics, Inc.Not disclosed
  8. 8Amylyx PharmaceuticalsNot disclosed
  9. 9Anavex Life SciencesNot disclosed
  10. 10Arcturus Therapeutics HoldingsNot disclosed
  11. 11Astria Therapeutics, Inc.Not disclosed
  12. 12Atea Pharmaceuticals, Inc.Not disclosed
  13. 13Gossamer Bio, Inc.Not disclosed
  14. 14Inhibrx Biosciences, Inc.Not disclosed
  15. 15MBX Biosciences, Inc.Not disclosed
  16. 16Rezolute, Inc.Not disclosed
  17. 17Terns Pharmaceuticals, Inc.Not disclosed
  18. 18Tyra BiosciencesNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.